Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 908-114-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity: NOAEL is 100 mg/kg bw, based on read-across from Geraniol 60 (Geraniol 60/Nerol 40%). Two studies are used to cover this repeated dose endpoint: The repeated dose toxicity from the OECD TG 414 developmental toxicity study of Geraniol 60 is used for deriving the NOAEL. The 13 wk study (similar to OECD TG 408) of Geranyl (Citronellyl) Acetate is used to cover the key repeated dose toxicity parameters. Since the outcomes of the OECD TG 414 study with Geraniol 60 is more conservative than the outcomes of the Geranyl (Citronellyl) Acetate study and the observed effects are similar, the Geraniol 60 study is used as the leading result for NOAEL derivation and would also conservatively reflect the effects of the 13 wk sub-chronic study.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Species:
- rat
- Quality of whole database:
- The study used for read across was considered reliable (Klimisch 2).
Additional information
Repeated dose toxicity is assessed based on read-across from Geraniol 60 (Geraniol 60/Nerol 40%) and Geranyl (Citronellyl) Acetate and to Citronellyl Acetate Multi. The executive summaries of the source studies and additional information are presented below, followed by the read-across rationale.
Geraniol / Nerol (60/40% reaction mass called Geraniol 60) repeated dose effects from the developmental toxicity: OECD TG 414
For Geraniol / Nerol (60/40% reaction mass, Geraniol 60) a prenatal developmental study was performed according to OECD TG 414 and in compliance with GLP criteria. In this study, doses were 100, 300 and 1000 mg/kg bw/day test item in corn oil. The mean body weight gain of the mid and high dose rats was 13% and 14% lower than the control group. Based on these findings, the NOAEL for repeated dose toxicity in this study is 100 mg/kg bw.
Geranyl (Citronellyl as a minor constituent) acetate sub-chronic repeated dose toxicity similar to OECD TG 408
In a 13-week study, which was one of pre-studies done within a carcinogenicity study, with 10 rats/sex/dose, and test doses of 0, 250, 500, 1000, 2000 and 4000 mg/kg bw/day, rats were observed for clinical signs, morbidity, and mortality twice daily; rats were weighed weekly; necropsies were performed on all animals, histological examinations were performed on control and high-dose groups. In this study no test substance-related histopathological effects or increase in tumour-incidence were noted. Since the survival and the body weight gain was decreased in the high dose group (dosed at 4000 mg/kg bw/day) in males and females, the NOAEL of the 13-week study was established to be 2000 mg/kg bw/day.
In parallel the same set of tests (including the two-year carcinogenicity study) were performed with mice. The results in the mice studies were not considered to affect the conclusion based on the rat studies.
Other available information
This 13 wk study was a pre-study for a carcinogenicity study which is shortly presented below as well as an other preliminary study.
A carcinogenicity studywas conducted in which rats (n= 50/sex/dose) were exposed daily by gavage to Geranyl Acetate in corn oil at doses of 1,000 and 2,000 mg/kg bw/day for two years. Several pre-tests were performed in order to determine the final test concentrations in the carcinogenicity test. These pre-studies were reported to be performed with Geranyl Acetate containing 6-17% Citronellyl acetate mono.
In a 14-day studywith 5 rats/sex/dose, with test doses of 0, 62, 125, 250, 500 and 1000 mg/kg bw/day, rats were observed for clinical signs, morbidity, and mortality twice daily; rats were weighed weekly; necropsy was performed on all animals. No mortality was seen, weight gains by dosed and control groups were comparable. The activity of all rats that received 1,000 mg/ kg bw/day decreased after dosing between days 2 and 4 of the study. No compound-related effects were observed during necropsy.
The repeated dose toxicity of Citronellyl Acetate Multi using read across from Geraniol (Citronellyl) Acetate and Geraniol (CAS# 106-24-1)
Introduction and hypothesis for the analogue approach
Citronellyl Acetate Multi is a multi-constituent. The main constituent of Citronellyl Acetate Multi is Citronellyl Acetate mono. It has an unsaturated hydrocarbon backbone to which an acetic ester is attached. The minor constituent is Dihydro-Citronellyl Acetate which has the same structure except that it has a saturated hydrocarbon backbone. For this substance no repeated dose toxicity data are available. In accordance with Article 13 of REACH, lacking information should be generated whenever possible by means other than vertebrate animal tests, i.e. applying alternative methods such as QSARs, grouping and read-across. For assessing the repeated dose toxicity of Citronellyl Acetate Multi, the analogue approach is selected because for its key constituent Citronellyl Acetate mono and closely related analogues, Geraniol acetate and Geraniol 60 (Geraniol/Nerol reaction mass), repeated dose toxicity information is available, which can be used for read across.
Hypothesis: Citronellyl Acetate Multi has similar repeated dose toxicity as Citronellyl Acetate mono, Geranyl Acetate and Geraniol 60 based on similarities in hydrocarbon backbone, functional groups and similar metabolites. Conversion of toxicity values is not needed because the toxicity will be derived from its metabolites and these have lower NOAELs and MW compared to the acetate and as such conservative.
Available information: Citronellyl Acetate mono was tested in a 13 wk study as a mixture in Geranyl/Citronellyl Acetate (61/29%) with similar parameters recorded as in an OECD TG 408. A NOAEL of 2000 mg/kg bw is derived based on body weight effects (and mortality) at the next higher dose of 4000 mg/kg bw.
In addition, repeated dose toxicity information from Geraniol 60 (Reaction mass Geraniol 60/Nerol 40%), metabolites of impurities of Citronellyl Acetate mono) can be used for Citronellyl Acetate Multi from an OECD TG 414, in which maternal body weight decrease was seen >=300 mg/kg bw. A key NOAEL of 100 mg/kg bw was derived based on this effect.
Target chemical and source chemical(s)
Chemical structures of the target chemical and the source chemicals are shown in the data matrix, including physico-chemical properties and toxicological information, thought relevant for acute oral and dermal toxicity.
Purity / Impurities
The purity and impurities of the target chemical do not indicate acute oral toxicity potential other than indicated by the parent substance. The impurities are all below < 10%.
Analogue approach justification
According to Annex XI 1.5 read across can be used to replace testing when the similarity can be based on a common backbone and a common functional group. When using read across the result derived should be applicable for C&L and/or risk assessment and it should be presented with adequate and reliable documentation, which is presented below.
Analogue selection: The one study performed with metabolites of the impurities (Geraniol 60) is selected as key study because this study and these metabolites are considered to present conservative values for repeated dose toxicity.
Structural similarities and differences: All constituents of Citronellyl Acetate Multi, including Citronellyl Acetate mono, have a similar backbone and functional group. These are all acetate esters of a 3,7-dimethyloctanol chain only differing in the number and/or position of the unconjugated double bonds in the hydrocarbon chain.
One analogue is Geranyl Acetate/Citronellyl Acetate (61/29% as tested in the NTP repeated dose toxicity study). The minor constituent tested in the NTP study is the key constituent in the current test substance.
The other analogue used is Geraniol 60, which consists of ca 60% of geraniol (‘trans-geraniol’) and 40% Nerol (‘cis-geraniol’). These have the same similar backbone. Instead of the acetate ester a primary alcohol is the functional group.
Toxico-kinetic: Systemic exposure: Citronellyl Acetate Multi, Geranyl /Citronellyl acetate and Geraniol will give similar systemic exposure based on the similarity in backbone structure and metabolites. Metabolism: The ester bond present in the acetate ester of all components of Citronellyl Acetate Multi and Geranyl Acetate is expected to behydrolysed into the respective alcohol and acetic acid due to activity of carboxylases in e.g. gut and liver and other living ti. For Geranyl acetate this has been experimentally shown (see toxico-kinetic record). This shows that there will be no systemic exposure to the acetates.
Compared to Citronellyl Acetate Multi’ key constituents Geraniol has some more metabolites (5 and 6 versus 14 metabolites) and several of these are more reactive ones due to conjugation of the ester or alcohol bond as predicted by the OECD Toolbox, See Annex 1 and 2).
Toxico-dynamics: The effects of Citronellyl acetate Multi are expected to be body weight (gain) decrease type of effects at high doses as was seen for Geranyl/Citronellyl acetate in the NTP study and for Geraniol 60, despite that Geraniol has some more reactive metabolites compared to Citronellyl Acetate Multi’s constituents as presented in the Annexes below. Therefore the read across may be considered conservative.
Uncertainty of the prediction: There are or no uncertainties other than addressed above.
Data matrix
The relevant information on physico-chemical properties and toxicological characteristics are presented in the Data Matrix.
Conclusions on repeated dose toxicity
For Citronellyl Acetate Multi as such no repeated dose toxicity information is available but for its constituents/impurity or the metabolites such information is available. For Geranyl/Citronellyl Acetate and for Geraniol/ Nerol (60/40% reaction mass; Geraniol 60) there is repeated dose toxicity information which can be used for read across, can fill the data gap and the read across is adequately and reliably documented.The 13-wk information from Geranyl (and Citronellyl) acetate repeated dose (similar to OECD TG 408) fulfils most of the repeated dose parameters and a NOAEL of 2000 mg/kg bw is derived.For deriving the NOAEL for repeated dose toxicity the maternal toxicity in an OECD TG 414 with Geraniol / Nerol (60/40% reaction mass; Geraniol 60) is used because this is the lower NOAEL: 100 mg/kg bw. Conversion is not needed because the available repeated dose toxicity shows that the NOAEL for non pregnant females is higher. Also no MW conversion is needed because Geraniol 60 has the lower MW.
Final conclusion: For Citronellyl Acetate Multi the NOAEL is 100 mg/kg bw
Data matrix presenting the information relevant for read across to Citronellyl Acetate Multi from Geranyl Acetate/Citronellyl acetate and Geraniol for repeated dose toxicity
Substance |
Citronellyl Acetate Multi |
Citronellyl Acetate mono constituent |
Dihydro-Citronellyl Acetate constituent |
Geranyl acetate impurity |
Geraniol (trade name: Geraniol 60) |
Read-across |
Target |
Target |
Target |
Source |
Source |
Structure |
See constituents |
||||
% in product |
See constituents |
60-75 |
10-20 |
<10 |
n.a. |
CAS |
See constituents |
150-84-5 |
20780-49-8 |
105-87-3 |
106-24-1/106-25-2 |
EC number |
904-114-0 |
205-775-0 |
244-034-6 |
203-341-5 |
906-125-5 |
REACH |
Registered |
Registered |
Registered |
Registered |
Registered |
MW |
See constituents |
198 |
200 |
196 |
154 |
Phys-chem |
|
|
|
|
|
Appearance |
Liquid |
-- |
Liquid (ECHA site) |
Liquid (ECHA site) |
Liquid (ECHA site) |
Log Kow |
4.6 (exp) |
4.6 (ECHA site) |
4.6 (ECHA site) |
4.5 (ECHA site) |
3.5 (ECHA site) |
Ws (mg/L) |
12.1 (exp) |
5.7 (ECHA site) |
4.7 (ECHA site) |
18.2 (ECHA site) |
>1000 (ECHA site) |
Vp (Pa) |
2.6 (exp) |
7.0 (ECHA site) |
12.9 (ECHA site) |
6.2 (ECHA site) |
2.12 (ECHA site) |
Human health |
|
|
|
|
|
Repeated dose toxicity mg/kg bw |
NOAEL: 100 (RA from Geraniol 60) |
See Multi |
See Multi |
NOAEL: 2000 (Geranyl 61%/ Citronellyl 29 %) tested in a similar to OECD TG 408) |
NOAEL: 100 (OECD TG 414) |
RA = read-across.
Annex 1: OECD Toolbox Profiling of Citronellyl Acetate mono, Dihdro-Citronellyl Acetate and Geraniol and the metabolites
OECD Toolbox profiler for Citronellyl Acetate mono, Dihydro-Citronellyl Acetate and Geraniol
OECD Toolbox Metabolite profiling of metabolites of Citronellyl Acetate mono, Dihydro-Citronellyl Acetate and Geraniol
Justification for classification or non-classification
Based on the absence of adverse effects in reliable repeated dose toxicity studies, the substance does not need to be classified for repeated dose toxicity by the oral route according to EU CLP (EC No. 1272/2008, and its amendments).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.